SYNLOGIC, INC. (SYBX)
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Synlogic, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 12.25M shares outstanding
USSynlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States.
Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate to treat homocystinuria; and SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase I clinical trial for the treatment of enteric hyperoxaluria.
The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine that is in Phase I clinical trial to treat solid tumors and lymphoma.
It has a collaboration agreement with F. Hoffmann-La Roche Ltd; Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.
Leadership
Aoife Brennan
President and Chief Executive Officer
Edward Mathers
Lisa Kelly-Croswell
Michael Burgess
Employees
1
Country
US
Sector
Healthcare
Website
synlogictx.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 New Enterprise Associates 14, L.P. | Director | Expiration (Long) | 2.64M | -- | Jul 27, 2026 |
| New Enterprise Associates 14, L.P. | Director | Purchase | 2.64M | -- | Jul 27, 2026 |
 Dooley Mary Beth | Head of Finance | Sale | 157 | $284.17 | Oct 29, 2025 |
 Shea Richard P | Director | Grant/Award | 15.0K | -- | Apr 26, 2025 |
 Flynn James P | Director | Grant/Award | 15.0K | -- | Apr 26, 2025 |
| Dooley Mary Beth | Head of Finance | Sale | 144 | $172.8 | Apr 2, 2025 |
| Name | Shares | % | Source |
|---|---|---|---|
Cable Car Capital, LP · joint filing· may incl. warrants· filed Jul 2026 | 3.3M | 27.0% | 13D |
NEA 14 GP, LTD · joint filing· may incl. warrants· filed Jul 2026 | 2.9M | 23.9% | 13D |
DRW Securities, LLC | 23.8K | 0.2% | 13F |
 Shea Richard P Director | 15.5K | 0.1% | FORM 4 |
 Flynn James P Director | 15.0K | 0.1% | FORM 4 |
 Dooley Mary Beth Head of Finance | 12.7K | 0.1% | FORM 4 |
Insiders
- New Enterprise Associates 14, L.P.Director
- Dooley Mary BethHead of Finance
- Shea Richard PDirector
- Flynn James PDirector
Top institutional holders
based on 12.25M shares outstanding
US30d Avg
32.25K
60d Avg
24.78K
90d Avg
40.02K